CA-XRAN-FOUNDATION
27.2.2017 08:03:01 CET | Business Wire | Press release
The xRAN Foundation, a consortium dedicated to promoting a software-based, extensible Radio Access Network (xRAN) and to standardizing critical elements of the xRAN architecture, today announced that Verizon, a global leader of innovative mobile communications, technology and infrastructure and Ranzure, a provider of flexible, virtualized, cloud-based 4G/5G RAN solutions, have joined the xRAN Foundation. In addition to these key new members, the xRAN Foundation has announced a collaboration with M-CORD , the open source project reinventing network access to bring datacenter economics and cloud agility to service providers’ central offices.
“A network architecture that provides a robust, interactive abstraction layer between applications and RAN infrastructure fits very well with our vision and goals. We believe this approach creates opportunities to increase the efficiency of our network and improve the quality of experience for our subscribers,” said Adam Koeppe, Vice President, Network Technology Planning at Verizon. “The xRAN Foundation has demonstrated the feasibility of a decoupled approach. The combination of standardized north-bound and south-bound interfaces allows the development of applications that can intelligently interact with the RAN infrastructure in a way that has never been possible before. We are excited to join the xRAN Foundation and plan to actively evaluate solutions that support xRAN interfaces and architecture.”
“For an efficient delivery of next generation mobile services, such as AR, IoT and industrial robotics, a new more flexible software-based and hardware independent RAN architecture is required. The xRAN approach will offer us real time programmability and control of our RAN infrastructure to dynamically adapt to our customers' needs,” said Bruno Jacobfeuerborn, CTO, Deutsche Telekom. “We are excited to see xRAN and CORD Project join forces to drive the development of this approach.”
Formally formed in October of 2016 by AT&T, Deutsche Telekom, SK Telecom, Intel Corporation, Texas Instruments, Radisys, Aricent and Stanford University, the xRAN Foundation is a consortium dedicated to promoting a software-based, extensible Radio Access Network (xRAN) and to standardizing critical elements of the xRAN architecture. The xRAN architecture transforms today’s static, highly-proprietary RAN infrastructure into an extensible, software-based service delivery platform capable of rapidly responding to changing user, application and business needs.
The xRAN Foundation is holding a panel discussion event at Mobile World Congress 2017 in Barcelona on Tuesday February 28th at noon on the Deutsche Telekom main presentation stage in Hall 3. The event will include an introduction presentation by Deutche Telekom CTO, Bruno Jacobfeuerborn, followed by a panel discussion moderated by Petr Ledl, Head of Deutsche Telekom 5G:haus. The panel includes Dr. Sachi Katti, Stanford University, Dr. Kim Larsen, Technology Economics & Transformation (TET) & AI Technology Architecture & Innovation (TAI) Group Technology at Deutsche Telekom, Gordon Mansfield, Vice President RAN & Device Design at AT&T, and Caroline Chan, VP and GM, 5G Infrastructure Division, Network Platform Group, at Intel.
A multi-vendor demonstration of the xRAN controller, featuring the Intel + Radisys and the Texas Instruments + Aricent reference platforms, will be hosted during Mobile World Congress. Register for a demo here: http://xran.org/mwc
About xRAN Foundation
The xRAN Foundation was formed to develop, standardize and promote an open alternative to the traditionally closed, hardware-based RAN architecture. xRAN fundamentally advances RAN architecture in three areas – decouples the RAN control plane from the user plane, builds a modular eNB software stack that operates on common-off-the-shelf (COTS) hardware and publishes open north- and south-bound interfaces to the industry. For more information about xRAN Foundation membership go to xran.org/membership or email info@xran.org . For more information on xRAN architecture, download the xRAN Architecture white paper . To schedule a briefing with xRAN member representatives at Mobile World Congress in Barcelona, please contact pr@xran.org .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170226005155/en/
Contact:
xRAN Foundation
Rod Stuhlmuller
rod@xran.org
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom